Clenbuterol to Target DUX4 in FSHD
Clenbuterol to Target DUX4 in FSHD
Recruiting · NCT06721299 · Registry updated 2026-02-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clenbuterol to Target DUX4 in FSHD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 | 2026-02-25 | NCT06721299 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jeffrey Statland | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 108 |
| University of Rochester | 189 |
| University of Washington | 397 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Kansas Medical Center | Kansas City | United States | 240 |
| University of Rochester Medical Center | Rochester | United States | 162 |
| University of Washington | Seattle | United States | 31 |